Erasca Inc
ERAS3.480USD
+0.050+1.46%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
987.32MMarket Cap
LossP/E TTM
More Details of Erasca Inc Company
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Erasca Inc Info
Ticker SymbolERAS
Company nameErasca Inc
IPO dateJul 15, 2021
CEOLim (Jonathan E)
Number of employees103
Security typeOrdinary Share
Fiscal year-endJul 15
Address3115 Merryfield Row
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18584656511
Websitehttps://www.erasca.com/
Ticker SymbolERAS
IPO dateJul 15, 2021
CEOLim (Jonathan E)
Company Executives of Erasca Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
21.17K
+37.11%
Dr. Shannon R. Morris, M.D., Ph.D.
Dr. Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
--
--
Dr. Valerie Harding-Start, Ph.D.
Dr. Valerie Harding-Start, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Independent Director
Independent Director
--
--
Dr. Michael David Varney, Ph.D.
Dr. Michael David Varney, Ph.D.
Director, Chair of Research and Development and Scientific Advisory Board member
Director, Chair of Research and Development and Scientific Advisory Board member
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
21.17K
+37.11%
Dr. Shannon R. Morris, M.D., Ph.D.
Dr. Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
8.01%
T. Rowe Price Investment Management, Inc.
7.13%
Lim (Jonathan E)
6.86%
VR Adviser, LLC
6.29%
Logos Global Management LP
5.34%
Other
66.37%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
8.01%
T. Rowe Price Investment Management, Inc.
7.13%
Lim (Jonathan E)
6.86%
VR Adviser, LLC
6.29%
Logos Global Management LP
5.34%
Other
66.37%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.44%
Venture Capital
22.03%
Hedge Fund
16.09%
Private Equity
8.01%
Individual Investor
7.33%
Investment Advisor/Hedge Fund
5.93%
Corporation
4.34%
Research Firm
1.39%
Bank and Trust
0.10%
Other
7.34%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
302
232.29M
89.71%
--
2025Q3
310
232.29M
93.65%
-60.69K
2025Q2
313
232.41M
93.79%
-6.69M
2025Q1
306
239.26M
97.34%
-36.46M
2024Q4
312
245.09M
99.26%
-1.10M
2024Q3
302
246.05M
87.29%
+28.86M
2024Q2
292
216.94M
64.16%
+84.80M
2024Q1
269
85.99M
67.39%
-16.11M
2023Q4
259
82.61M
63.62%
+857.42K
2023Q3
245
88.19M
71.92%
-4.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
22.73M
8.01%
+153.59K
+0.68%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
20.33M
7.17%
+3.04M
+17.58%
Jun 30, 2025
Lim (Jonathan E)
19.46M
6.86%
--
--
Apr 15, 2025
VR Adviser, LLC
17.86M
6.29%
+1.64M
+10.12%
Jun 30, 2025
Logos Global Management LP
15.00M
5.29%
+2.00M
+15.38%
Jun 30, 2025
Suvretta Capital Management, LLC
14.50M
5.11%
+2.19M
+17.76%
Jun 30, 2025
Paradigm BioCapital Advisors LP
11.91M
4.2%
+1.10M
+10.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
13.32M
4.7%
-725.47K
-5.16%
Jun 30, 2025
City Hill Ventures, LLC
12.90M
4.55%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
12.70M
4.48%
+9.22K
+0.07%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.07%
ALPS Medical Breakthroughs ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.03%
ProShares UltraPro Russell2000
0.02%
iShares US Small-Cap Equity Factor ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.07%
ALPS Medical Breakthroughs ETF
Proportion0.28%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.02%
iShares US Small-Cap Equity Factor ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Erasca Inc?
The top five shareholders of Erasca Inc are:
Frazier Life Sciences Management, L.P. holds 22.73M shares, accounting for 8.01% of the total shares.
T. Rowe Price Investment Management, Inc. holds 20.33M shares, accounting for 7.17% of the total shares.
Lim (Jonathan E) holds 19.46M shares, accounting for 6.86% of the total shares.
VR Adviser, LLC holds 17.86M shares, accounting for 6.29% of the total shares.
Logos Global Management LP holds 15.00M shares, accounting for 5.29% of the total shares.
Frazier Life Sciences Management, L.P. holds 22.73M shares, accounting for 8.01% of the total shares.
T. Rowe Price Investment Management, Inc. holds 20.33M shares, accounting for 7.17% of the total shares.
Lim (Jonathan E) holds 19.46M shares, accounting for 6.86% of the total shares.
VR Adviser, LLC holds 17.86M shares, accounting for 6.29% of the total shares.
Logos Global Management LP holds 15.00M shares, accounting for 5.29% of the total shares.
What are the top three shareholder types of Erasca Inc?
The top three shareholder types of Erasca Inc are:
Frazier Life Sciences Management, L.P.
T. Rowe Price Investment Management, Inc.
Lim (Jonathan E)
Frazier Life Sciences Management, L.P.
T. Rowe Price Investment Management, Inc.
Lim (Jonathan E)
How many institutions hold shares of Erasca Inc (ERAS)?
As of 2025Q4, 302 institutions hold shares of Erasca Inc, with a combined market value of approximately 232.29M, accounting for 89.71% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.94%.
What is the biggest source of revenue for Erasca Inc?
In --, the -- business generated the highest revenue for Erasca Inc, amounting to -- and accounting for --% of total revenue.
